Tecartus (brexucabtagene autoleucel) / Gilead, Fosun Kite - LARVOL DELTA

Comparative safety profiles of bispecific T-cell engagers and CAR-T therapies: Real-world insights from the FDA adverse event reporting system database (ASH 2025) - "BiTEs demonstrated a significantly higher disproportionality signal for neutropenia compared to CAR-T therapies (PRR=1.74, ROR=1.93, 95% CI [1.89, 1.98], p<0.001), with Glofitamab showing the highest reporting rate (42.2%) among BiTEs...Tisagenlecleucel had the highest hepatotoxicity rate (4.1%) among CAR-T agents...Axicabtagene ciloleucel had the highest venous thrombosis rate (42.6%) among CAR-T agents...Brexucabtagene autoleucel had the highest rate of arterial thrombosis (0.78%) among CAR-T agents. This real-world analysis reinforces the well-characterized neurotoxicity associated with CAR-T therapies, while highlighting the higher rate of neutropenia with BiTEs. These distinct toxicity profiles emphasize the importance of individualized treatment selection, considering patient comorbidities, toxicity tolerance, logistical factors, and the clinical context, which includes the potential for better disease control with specific therapies."

Adverse events • Clinical • Real-world • Real-world evidence • Acute Kidney Injury • Cardiovascular • Hematological Malignancies • Hepatology • Nephrology • Neutropenia • Renal Disease • Thrombosis • ROR1

Analysis of the cost-effectiveness without compromising clinical outcomes in outpatient CD19-directed CAR-T therapy in non-Hodgkin lymphoma patients at a community-based medical center (ASH 2025) - "Secondary objectives included assessment of toxicity, response, and survival in patients receiving axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), or tisagenlecleucel (tisa-cel)...In 2024, one patient received prophylactic dexamethasone prior to infusion... Based on CMS data and the ZUMA-1 trial, the median inpatient stay for CAR-T therapy is approximately 15 days, with Medicare reimbursing an average of $498,700 per admission. This includes the high cost of the CAR-T product and the intensive inpatient care needed to manage toxicities like CRS and ICANS. In contrast, a typical 7-day inpatient hospital stay costs Medicare only $13,000 to $18,000."

Clinical • Clinical data • Cost effectiveness • HEOR • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma

Aberrant lymphocytes are associated with increased inflammatory complications following CAR-T infusion (ASH 2025) - "CAR-T products included axi-cel (Yescarta) (n=10), brexu-cel (Tecartus) (n=2), liso-cel (Breyanzi) (n=1), tisa-cel (Kymriah) (n=1), or CD19-Car_Lenti (produced by the Officina Farmaceutica of Bambino Gesù Children's Hospital) (n=2)...Associations were not found between number of aberrant lymphocytes and development of neurotoxicity (eg, ICANS) nor with doses of Tocilizumab, Dexamethasone, or Anakinra or with WBC. While the number of patients is small, presence of increased aberrant lymphocytes, as pre-classified by the Scopio full-field digital morphology platform, appears to be associated with increased inflammatory complications following CAR-T infusion, including CRS of grade ≥2 and prolonged neutropenia requiring G-CSF support. Digital morphology combined with artificial intelligence may represent a novel platform for predicting clinical outcomes in CAR-T therapy."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Rheumatology

Comparative efficacy and safety of bendamustine versus fludarabine and cyclophosphamide as lymphodepleting regimens for CAR-T therapy in hematological malignancies: A systematic review and meta-analysis (ASH 2025) - "Axicabtagene ciloleucel was used in four studies, brexucabtagene autoleucel and tisagenlecleucel in two studies, and lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel in one study each. These findings suggest that bendamustine may serve as a viable alternative LD regimen, especially for patients at high risk of infections. Further prospective studies are warranted to confirm the safety and efficacy of bendamustine compared to standard FluCy regimen."

Retrospective data • Review • Acute Lymphocytic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

CAR t-cell therapy-related cytokine release syndrome and neurotoxicity: Real-world outcomes from a comprehensive cancer center (ASH 2025) - "Treatment options included ciltacabtagene autoleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel...Secondary outcomes included use of tocilizumab, corticosteroids, vasopressors, anakinra, intrathecal chemotherapy, dasatinib, and thiamine; length of stay; survival at 100 days and 1 year... 53 patients were included in the study. Most patients receiving axi-cel experienced grade 1 or 2 CRS, with only three patients experiencing grade ≥3 CRS. The incidence of CRS was lower here compared to ZUMA-1 and ZUMA-5."

CAR T-Cell Therapy • Clinical • Cytokine release syndrome • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Title: Association of CAR-T product type with incidence of cancer Therapy–Related cardiac dysfunction (CTRCD) (ASH 2025) - " Five CAR-T products were evaluated for their association with CTRCD: axicabtagene ciloleucel, idecabtagene vicleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, and ciltacabtagene autoleucel. In this retrospective study of CAR-T recipients, the overall incidence of cancer therapy-related cardiac dysfunction (CTRCD) was notable at 39%, with variability observed across CAR-T products. Axicabtagene ciloleucel demonstrated the highest rate of CTRCD, while no events were seen with brexucabtagene autoleucel or ciltacabtagene autoleucel. Despite these trends, statistical analyses did not reveal a significant association between CAR-T product type and CTRCD incidence."

Hematological Malignancies • Immunology • Oncology • Systemic Inflammatory Response Syndrome • IL6

Real-world patterns of secondary malignancies and relapse following CAR T-cell therapy: A faers pharmacovigilance analysis (ASH 2025) - "Six CAR T-cell products have been approved by the U.S. Food and Drug Administration (FDA) to date: tisagenlecleucel (Tisa-cel), axicabtagene ciloleucel (Axi-cel), brexucabtagene autoleucel (Brexu-cel), lisocabtagene maraleucel (Liso-cel), ciltacabtagene autoleucel (Cilta-cel), and idecabtagene vicleucel (Ida-cel), for pediatric and adult B-cell acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma, follicular lymphoma and mantle cell lymphoma. Our FAERS analysis reveals distinct patterns of secondary primary malignancies and relapsed diseases following CAR T-cell therapy in real-world settings. The identification of myelodysplastic syndromes, cutaneous neoplasms, and rare T-cell or solid tumors highlights the need for vigilant post-therapy surveillance."

Adverse events • CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Basal Cell Carcinoma • Brain Cancer • Carcinoid Tumor • Diffuse Large B Cell Lymphoma • Endocrine Cancer • Eye Cancer • Follicular Lymphoma • Gastric Cancer • Glioblastoma • Glioneuronal Tumor • Head and Neck Cancer • Hematological Malignancies • Kaposi Sarcoma • Leiomyosarcoma • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Merkel Cell Carcinoma • Multiple Myeloma • Myelodysplastic Syndrome • Neuroendocrine Carcinoma • Non-Hodgkin’s Lymphoma • Non-melanoma Skin Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Peripheral T-cell Lymphoma • Rhabdomyosarcoma • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • T Cell Non-Hodgkin Lymphoma

Endocrine adverse events following CAR-T cell therapies: A pharmacovigilance analysis in the real-world setting utilizing the faers database (ASH 2025) - "CAR-T products analyzed included axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel, idecabtagene vicleucel, and lisocabtagene maraleucel. This FAERS-based real-world analysis identifies relevant endocrine toxicities linked to CAR-T therapies, with strongest associations observed for axicabtagene ciloleucel and tisagenlecleucel. Immune-mediated dysfunction in the pituitary and thyroid axes appears most prominent. These findings support the need for increased endocrine monitoring post-CAR-T and suggest a class-wide effect with further prospective study."

Adverse events • CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Cushing’s Disease • Diabetes • Endocrine Disorders • Hematological Malignancies • Immunology • Metabolic Disorders • Nephrology • Renal Disease

Comparative analysis of CAR-T cell therapies across lymphoma subtypes: Efficacy, safety, and future perspectives (ASH 2025) - "Toxicity varied by costimulatory domain: CD28-based constructs (axi-cel) were associated with higher rates of CRS and immune effector cell-associated neurotoxicity syndrome than 4-1BB-based (costimulatorydomain) constructs (liso-cel, tisa-cel)...In mantle cell lymphoma (MCL), brexucabtagene autoleucel reduced or eliminated cancer in 93% of patients, with complete disappearance seen in 67%... C AR-T therapy offers subtype-specific advantages, with FL showing higher response rates and MCL demonstrating superior progression-free survival. While efficacy is well established, toxicity and relapse remain the key concerns. Costimulatory domains influence toxicity, and dual-target CAR-Ts may mitigate antigen escape."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • CD22

Absolute lymphocyte count (ALC) at apheresis and infusion as a predictor of safety and efficacy for multiple myeloma and B cell malignancies post CAR-T therapy (ASH 2025) - "72% of the population had diffuse large B-cell lymphoma (DLBCL) and 65% of the cohort received axicabtagene ciloleucel...68% of this group had IgG MM and 52% of the cohort received idecabtagene vicleucel...56% of the ALL cohort received brexucabtagene autoleucel... ALC at time of apheresis and infusion may influence progression/survival status and incidence of CRS/ICANS. ALC at apheresis may be predictive of the quantity of lymphocytes being collected and ALC at infusion may effect CAR-T expansion by impacting the cellular immune environment. These findings were more pronounced in the NHL cohort than in the MM or ALL cohorts, which may reflect the effect of disease specific characteristics as well as the confounder of circulating leukemic cells registering as lymphocytes."

Clinical • Acute Lymphocytic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma (ASH 2025) - "Seventeen pts (65%) had prior bendamustine at a median of 48 months prior to brexu-cel, and eleven pts (42%) had been on multiple Bruton tyrosine kinase inhibitors (BTKi). In a high-risk, heavily pre-treated cohort of pts with MCL, CAR-T therapy was associated with high response rates and toxicity consistent with previously published series. A relative increase in ferritin after D0 was associated with both high-grade CRS and ICANS, and late CAR-T cell expansion was associated with neurotoxicity. If confirmed in larger studies, early interventions to mitigate inflammatory response and dampen the CAR-T cell peak can be explored to improve the therapeutic index of brexu-cel."

CAR T-Cell Therapy • IO biomarker • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • CRP • TP53

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma (ASH 2025) - " The single institution cohort includes patients with a diagnosis of R/R NHL after ≥1 line of prior therapy treated with axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, or tisagenlecleucel. In this contemporary, large, single-institution cohort study, we show that pre-lymphodepletion CAR is associated with relapse and overall survival after adjustment for other well-established risk factors. Since CAR is a dynamic, readily available estimate of the inflammatory and nutritional state as demonstrated previously in other cancer types, these results suggest that it can also be applied to the setting of CAR T therapy for R/R NHL, in combination with pre-treatment disease burden as measured by LDH. Our results support our previous findings on the crucial role of inflammation in CAR T and cancer immunotherapy outcomes, and lend support to a rational target for therapeutic and behavior intervention."

CAR T-Cell Therapy • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CRP

A post-marketing pharmacovigilance analysis of cardiotoxicities following chimeric antigen receptor T-cell therapy using the FDA adverse event reporting system (ASH 2025) - "Therefore, a post-marketing pharmacovigilance analysis of the cardiac AEs reported to the FDAAdverse Event Reporting System (FAERS) for each CAR-T product was conducted to address thisknowledge gap. All individual case safety reports of cardiac AEs listing any of the approved CAR-T therapies[Tisagenlecleucel (Tisa-cel), Axicabtagene ciloleucel (Axi-cel), Lisocabtagene maraleucel (Liso-cel),Brexucabtagene autoleucel (Brexu-cel), Idecabtagene vicleucel (Ide-cel), Ciltacabtagene autoleucel (Cilta-cel) and Obecabtagene autoleucel (Obe-cel)] as the suspected drug were identified from the FAERSdatabase... This post-marketing pharmacovigilance analysis highlights patterns of cardiac AEs followingCAR-T therapy. Trends in AEs based on CAR-T product, age, and sex support the ongoing need forvigilance for these unique toxicities. As this study is limited by FAERS reporting bias, prospective studiesto validate these associations and elucidate the underlying mechanisms are needed,..."

Adverse events • CAR T-Cell Therapy • P4 data • Acute Coronary Syndrome • Acute Lymphocytic Leukemia • B Cell Non-Hodgkin Lymphoma • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Hypotension • Leukemia • Lymphoma • Multiple Myeloma • Myocardial Infarction • Non-Hodgkin’s Lymphoma • Thrombosis • ROR1

Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma (ASH 2025) - "In this retrospective study, wefocus on the impact of pre-existing cognitive impairment on CAR T therapy outcomes in a larger,contemporary cohort of patients with NHL.The single instituion cohort includes patients with a diagnosis of R/R NHL after ≥1 line of therapy whoreceived axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, ortisagenlecleucel. In this contemporary, large, single-institution cohort study, we show that pre-exisiting cognitiveimpairment prior to CAR T therapy is associated with significantly reduced OS independent of other well-established risk factors. While the underlying mechanism may be multifactorial, cognitive impairment, asa marker of frailty among older patients, may contribute to these patients' decreased ability to tolerateadditional, post-relapse therapy. We are currently planning a multi-center validation study, andconducting a prospective, pilot interventional study to target cognitive impairment during CAR T..."

CAR T-Cell Therapy • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Epilepsy • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Association between pre-existing mental health history and higher risk of mental health outcomes post-CAR-t therapy in patients with hematologic malignancies (ASH 2025) - "CAR-T therapies included tisagenlecleucel, brexucabtagene autoleucel, axicabtagene ciloleucel,lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel. This analysis offers a unique perspective on the mental health trajectories of CAR-T therapyrecipients, considering their pre-treatment mental health status. The findings indicate that individualswithout prior mental health disorders exhibited a substantially lower risk of developing mental healthissues following CAR-T therapy. In contrast, patients with pre-existing mental health comorbiditiesdemonstrated a statistically significant increase in the incidence of mood disorders, anxiety, andbehavioral syndromes post-treatment."

Clinical • HEOR • CNS Disorders • Hematological Malignancies • Mood Disorders • Oncology • Psychiatry

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (ASH 2025) - P1/2 | "Two (9.1%) pts received bendamustinewithin 12 mo prior to leukapheresis and 3 (13.6%) pts received bridging therapy (radiation [RT], n=2; RTand venetoclax, n=1). The CAR T-cell therapies received were axicabtagene ciloleucel (n=12),brexucabtagene autoleucel (n=3), tisagenlecleucel (n=2), lisocabtagene maraleucel (n=1), and aninvestigational CD19-targeted CAR T-cell therapy (n=4)... This real-world multicenter analysis suggests that prior Mosun treatment does not impairthe efficacy of subsequent CAR T-cell therapy in pts with R/R B-NHL, with the safety profile consistentwith previously published data. These results support CAR T-cell therapy as a viable treatment optionfollowing BsAb treatment. Further studies are needed to fully characterize and validate the efficacy andsafety of CAR T-cell therapy after BsAbs such as Mosun."

CAR T-Cell Therapy • Clinical • Acute Kidney Injury • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock

Immune effector cell-associated enterocolitis (IEC-EC) across CAR-T products in myeloma and lymphoma: A real world pharmacovigilance analysis (ASH 2025) - "Introduction: IEC-EC has emerged as a unique toxicity of BCMA-targeted CAR-T therapy in multiple myeloma (MM)patients (pts), most commonly with ciltacabtagene autoleucel (cilta-cel) (G...Reports were distributed as follows: axicabtagene ciloleucel (axi-cel, 57.6%,n=7828), cilta-cel (19.5%, n=2647), brexucabtagene autoleucel (brexu-cel, 11.9%, n=1615), idecabtagenevicleucel (ide-cel, 6.9%, n=933), and lisocabtagene maraleucel (liso-cel, 4.7%, n=641)...Compared with checkpoint inhibitors, cilta-cel-associated IEC-EC rates (1.02%) exceeded those for the PD-1 agents nivolumab (0.23%), pembrolizumab(0.13%) and the CTLA-4 inhibitor ipilimumab (0.46%)... Our PV analysis reveals distinct GI SAE profiles among CAR-T therapies, with cilta-cel demonstrating aparticularly high signal for IEC-EC (ROR: 126.35, p<0.001). However, 3 cases occurred with axi-cel as well.The reported colitis rates well exceeded those observed with established checkpoint inhibitors,suggesting unique..."

Adverse events • Clinical • Real-world • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Lymphoma • Multiple Myeloma

Live-cell pick-seq (LiP-Seq): Interrogating ultra-rare Mantle Cell Lymphoma MRD after CD19-targeted CAR T-cell therapy (ASH 2025) - "Long-term follow-up of brexucabtagene autoleucel (KTE-X19) CAR T-celltherapy in R/R MCL reported 68% initial complete remissions (CRs), but only 37% progression-freesurvival at 3 years...These data, in combination with LiP-Seq of primary MRD specimens, highlightthe cell surface protein IFITM2 as a potential mediator of MRD survival and resistance to CD19 CAR T-celltherapy in MCL.In summary, LiP-Seq offers a novel platform capable of isolating and characterizing viable ultra-raretarget cells, providing unprecedented insights into MRD biology and facilitating downstream biologicalassays. In the setting of cancer MRD, this approach may identify important features with clinicalrelevance that are not obvious from studying more abundant tumor cells at other timepoints or diseasestates."

CAR T-Cell Therapy • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • CD5 • CD79B • IFITM3 • PTPRC

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients (ASH 2025) - "The most common CAR T-cell products wereaxicabtagene ciloleucel (n = 31, 25%), brexucabtagene autoleucel (n = 26, 21%), and tisagenlecleucel (n =21, 17%)...Nearly all (n = 123; 99%) patients received concurrent dexamethasone (dex) with a median totaldose of 234 mg (range, 30-690)...Sixteen patients (13%)received additional therapies, including ruxolitinib (n = 1), siltuximab (n = 3), cetuximab (n = 1), intrathecalchemotherapy (n = 11), and dasatinib (n = 1)...Higher dex doses remainedassociated with shorter time to ICANS resolution, highlighting that corticosteroids remain thecornerstone of treating refractory ICANS. More effective strategies for anakinra-refractory ICANS arecritically needed."

CAR T-Cell Therapy • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia (ASH 2025) - P1 | "NEJM 2025), and here we share our initial experiencetreating patients with R/R B cell acute lymphoblastic leukemia (ALL).MethodsIn a single center, first in human clinical trial utilizing huCART19-IL18 (NCT04684563), adult patients withR/R CD19+ ALL were eligible, including those with CNS disease and those with relapses after priorCART19, blinatumomab, and allogeneic transplant (alloHCT)...Subjects then receivedlymphodepleting (LD) fludarabine and cyclophosphamide followed by huCART19-IL18 infusion.ResultsAs of Aug...Subjects had a median of 5 (3-11) priorlines of therapy including alloHCT in 4 patients, blinatumomab in 4 (3 as salvage for post-alloHCT relapse),and brexucabtagene autoleucel in 2...Three patients received tocilizumab for CRS, and 1 received corticosteroids andanakinra for ICANS...All treated patients withadequate follow-up achieved early MRD-negative CR (including in the CNS), and there have been norelapses or deaths with a median follow-up of 15.1..."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • IL18

Blood and CSF metabolomics identifies tryptophan catabolism and polyamine synthesis as drivers of CAR T-cell-associated neurotoxicity (ASH 2025) - "Here weinvestigated the relationship between metabolic signatures and severity of NE following treatment withaxicabtagene ciloleucel (axi-cel) or brexucabtagene autoleucel (brexu-cel).We performed global metabolomic profiling on 3,788 longitudinal serum and plasma samples from amulti-trial meta-cohort of 686 patients treated with axi-cel (ZUMA-1, -5, -7, -12, -24) or brexu-cel (ZUMA-2).Additionally, we analyzed 60 cerebrospinal fluid (CSF) samples from 26 LBCL patients in ZUMA-1.Associations between metabolite levels and NE severity or clinical outcomes were assessed using mixed-effects models. This study represents the largest metabolomic analysis in the context of CAR-T cell therapy. We identifiedmetabolic pathways associated with severe neurotoxicity following anti-CD19 CAR T-cell therapy. Theresults support strategies for early identification and mitigation of neurotoxicity, including targetingtryptophan catabolism, NMDA receptor-mediated excitotoxicity and..."

CAR T-Cell Therapy • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma • CD14 • IL6 • TNFA

Impact of antibiotic timing on survival outcomes in CD19 and BCMA CAR-T cell therapy (ASH 2025) - "In particular, the PIM(piperacillin-tazobactam, imipenem, and meropenem) have been implicated with poor outcomes.This ispossibly related to dysregulation of the gut microbiome and/or impairment of hematopoietic recovery.Here, we aimed to investigate the effect of pre and post CAR-T antibiotics in patients receiving both CD19and BCMA CAR-T cell therapy. This is a single-center retrospective study of adult patients with multiple myeloma, B-celllymphoma, and acute lymphoblastic leukemia treated with autologous CD19 and BCMA targeting CAR-Tcell therapy at our center between April 2017 and August 2024. CD19 CAR-T cell products includedlisocabtagene maraleucel, tisagenlecleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel.BCMA CAR-T cell products included idecabtagene vicleucel and ciltacabtagene autoleucel...Post CAR-T antibiotics were largely fourthgeneration cephalosporins such as cefepime in combination with vancomycin... Exposure to antibiotics in the 30 days..."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

CD83 CAR T overcome CD19 antigen loss in B cell malignancies after CD19-directed therapy (ASH 2025) - "Therefore, CD83 CAR T therapy for B cell leukemia orlymphoma carries a low risk for B cell aplasia and related infectious complications, otherwise observedwith CD19 CAR T. In a cohort of B ALL patients treated with CD19-directed therapy (n=6, including brexucabtageneautoleucel or blinatumomab), CD19 antigen expression on lymphoblasts was significantly reduced uponrelapse. Sequential CD19=>CD83 CAR T cleared the tumor burdenin treated mice by day +48. Our preclinical evidence justifies further translational investigation of CD83CAR T in B cell leukemia and lymphoma, as a strategy to overcome the complications of B cell aplasia andCD19 antigen loss."

IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20 • CD22 • CD83 • IFNG • IL6 • PD-1

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study (ASH 2025) - "Axicabtagene ciloleucel was most common product (41%), followed by Tisagenlecleucel(26%), Brexucabtagene autoleucel (20%), and Lisocabtagene maraleucel (14%). About 8% of patients had an acute CVE within 30 days of CAR-T. While most patientsremained free of subsequent events, 23% of these survivors experienced a late CVE. Afib was thedominant CVE, both early and late."

Clinical • Acute Coronary Syndrome • Atrial Fibrillation • B Cell Lymphoma • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Follicular Lymphoma • Heart Failure • Hematological Malignancies • Hypertension • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Ventricular Tachycardia

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel) (ASH 2025) - "HR and SR pts had similar disease burden pre-apheresis (>5% blasts: 58% vs 53%), priorblinatumomab (60% vs 58%), prior inotuzumab (42% vs 46%), and prior allo HCT (27% vs 37%). To our knowledge, this analysis represents the largest examination of adult B-ALL recipients of CAR-Tassessed by genomic risk group. We found that response rates and survival outcomes following brexu-cel were similar among HR and SR B-ALL pts, including pts with TP53m and CRLF2r. However, pts withKMT2Ar had lower response rates and dismal EFS and OS, with higher rates of PD and myeloidtransformation at relapse, suggesting that alternative strategies are necessary to improve outcomes forpatients with R/R KMT2Ar B-ALL."

Adverse events • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Hematological Malignancies • Leukemia • CRLF2 • IKZF1 • JAK2 • KMT2A • TP53